Draupnir

3 known investors

Draupnir Bio develops oral small-molecule degraders of extracellular and membrane-bound pathogenic proteins using a proprietary platform that targets lysosome receptors, extending targeted protein degradation (TPD). The biotech company focuses on drug discovery for diseases driven by extracellular proteins.